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The Epstein-Barr virus LMP2A protein was expressed in a human keratinocyte cell line, HaCaT, and effects
on epithelial cell growth were detected in organotypic raft cultures and in vivo in nude mice. Raft cultures
derived from LMP2A-expressing cells were hyperproliferative, and epithelial differentiation was inhibited. The
LMP2A-expressing HaCaT cells were able to grow anchorage independently and formed colonies in soft agar.
HaCaT cells expressing LMP2A were highly tumorigenic and formed aggressive tumors in nude mice. The
LMP2A tumors were poorly differentiated and highly proliferative, in contrast to occasional tumors that arose
from parental HaCaT cells and vector control cells, which grew slowly and remained highly differentiated.
Animals injected with LMP2A-expressing cells developed frequent metastases, which predominantly involved
lymphoid organs. Involucrin, a marker of epithelial differentiation, and E-cadherin, involved in the mainte-
nance of intercellular contact, were downregulated in LMP2A tumors. Whereas activation of the mitogen-ac-
tivated protein kinase pathway was not observed, phosphatidylinositol-3-kinase (PI3-kinase)-dependent activa-
tion of the serine-threonine kinase Akt was detected in LMP2A-expressing cells and LMP2A tumors. Inhibition
of this pathway blocked growth in soft agar. These data indicate that LMP2A greatly affects cell growth and
differentiation pathways in epithelial cells, in part through activation of the PI3-kinase–Akt pathway.
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus of the
family Gammaherpesviridae. Primary infection occurs in the
oropharyngeal epithelium, which is permissive for virus repli-
cation. Trafficking B lymphocytes are subsequently infected by
progeny virions that go on to establish a lifelong latent infec-
tion in the B-cell compartment with periodic reactivation and
reinfection of the oropharyngeal epithelium, virus release, and
transmission of virus via the salivary route (27). EBV is asso-
ciated with a number of human malignancies, such as Burkitt’s
lymphoma, Hodgkin’s lymphoma, posttransplant lymphopro-
liferative disease, and the epithelial cell malignancy nasopha-
ryngeal carcinoma (NPC) (27, 42, 44–46, 56). In EBV latency,
only a subset of genes is expressed. Different types of latency
can be distinguished according to the latent gene products
expressed. In type I latency, characteristic of Burkitt’s lym-
phoma, only the EBV nuclear antigen 1 (EBNA1), tran-
scripts from the BamHI-A region of the genome (10), and
the EBERs, small, nonpolyadenylated RNAs with an un-
known function, are expressed. In B-cell lines immortalized
by EBV in vitro, all latent genes are expressed, which in-
clude EBNA1 through -6, BamHI-A transcripts, EBERs,
and three latent membrane proteins, LMP1, LMP2A, and
LMP2B (latency III). The pattern of gene expression is
more restricted in NPC, with expression of EBNA1, EBERs,
BamHI-A transcripts, and the latent membrane proteins (la-
tency II) (27).
LMP2A and -2B arise from two different promoters, and
transcription proceeds across the fused terminal repeats of the
viral episome (49). Whereas both proteins contains 12 trans-
membrane domains, only LMP2A has a 119-amino-acid cyto-
plasmic N terminus encoded by exon 1, which is unique to
LMP2A. The role of LMP2A has been analyzed mainly in B
cells, where it inhibits B-cell receptor signaling that would
induce EBV lytic replication (32). The LMP2A amino termi-
nus contains nine tyrosine residues, several of which are found
in the context of phosphotyrosine-containing protein-protein
interaction motifs. An immunoreceptor tyrosine-based activa-
tion motif (ITAM) is found at tyrosines 74 and 85. ITAMs
are characterized by the consensus sequence YXXL/I(X6–8)
YXXL/I and are present in associated molecules of the B- and
T-cell receptor signaling complexes, as well as the Fc receptor
complexes (55; M. Reth, Letter, Nature 338:383–384, 1989).
ITAMs, when phosphorylated by Src family kinases, serve as
docking sites for the tandem SH2 domains of the tyrosine
kinases Syk and ZAP70 in B and T cells, respectively. Activa-
tion of Syk in B cells lies upstream of multiple signal transduc-
tion events such as activation of phospholipase Cg2 and sub-
sequent stimulation of Ca21 release from intracellular stores
and activation of the Ras–mitogen-activated protein kinase
(MAPK) cascade. LMP2A is phosphorylated by Src family
kinases, Lyn and Fyn, in B cells, an event that depends on a
YEEA motif found in the LMP2A N terminus that closely
resembles the consensus sequence for Src SH2 domain inter-
action motifs, YEEI/L (11, 21, 23, 31). Binding of Lyn to this
motif at tyrosine 112 subsequently leads to phosphorylation of
the ITAM, which in turn is able to bind to and sequester Syk
(22). Additionally, LMP2A binds to and is phosphorylated by
the MAPK Erk1 (41). LMP2A interaction with components of
the B-cell receptor (BCR) signal transduction cascade results
in inhibition of these molecules and downstream processes
in response to BCR stimulation (35, 37). In the absence of
LMP2A expression, BCR engagement ultimately leads to the
activation of transcription factors which are able to induce the
expression of the EBV immediate-early genes BZLF1 and
BRLF1, followed by induction of viral lytic replication (36).
The negative regulation of BCR signals by LMP2A is thought
to contribute to the maintenance of viral latency. Genetic anal-
ysis of LMP2A indicated that LMP2A is not required for B-cell
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transformation (33, 34). However, studies with LMP2A trans-
genic mice have demonstrated that LMP2A expression under
certain circumstances enables B-cell survival (13).
Expression of both LMP2A and -2B has been detected in
NPC, and nude-mouse-passaged NPC tumors and NPC pa-
tients have high antibody titers to both LMP2A and -2B, indi-
cating that expression of the protein is important during some
stage of progression to disease (9, 12, 29). To investigate the
possible changes in epithelial cell behavior conferred upon
LMP2A expression, LMP2A was expressed in a spontaneously
immortalized human keratinocyte cell line, HaCaT (8). HaCaT
cells retain their potential to terminally differentiate in re-
sponse to various stimuli, such as growth in organotypic or
suspension cultures, and have been used in vitro to model
normal human squamous epithelium (52). In this study,
LMP2A was expressed in HaCaT cells by retrovirus-mediated
gene transfer and the phenotype of stable, LMP2A-expressing
pools was analyzed in organotypic raft culture, in soft agar, and
by subcutaneous injection into nude mice. The results indicate
that LMP2A has potent transforming abilities in HaCaT cells.
MATERIALS AND METHODS
Production of recombinant retroviruses. The LMP2A cDNA, carboxy termi-
nally tagged with a hemagglutinin (HA) epitope, was subcloned into the retro-
viral vector pBabe containing the puromycin resistance gene as a selectable
marker. Human 293T kidney cells were transiently transfected with 1 mg of the
vector pBabe or pBabe LMP2A, 1 mg of pGI-VSV-G (vesicular stomatitis virus
glycoprotein G envelope), and 1 mg of pGPZ9 (Moloney murine leukemia virus
gag-pol). At 48 h after transfection, culture supernatant was harvested and clar-
ified by centrifugation in a microcentrifuge at 16,000 3 g and 4°C. HaCaT cells
were transduced by incubation with retrovirus-containing 293T supernatant and
Polybrene at 8 mg/ml overnight. Following transduction, the cells were split into
dishes containing selection medium puromycin at 0.5 mg/ml). Stable colonies
were pooled after 2 weeks of selection.
Raft cultures. A 2.4-ml volume of rat tail collagen mixed with 3 3 105 normal
human fibroblasts was reconstituted with 300 ml of 103 Dulbecco modified Eagle
medium H (DMEM-H), 300 ml of 103 reconstitution buffer (2.2% NaHCO3, 50
mM NaOH, 200 mM HEPES [pH 7.3]), and 3 ml of 10 N NaOH and allowed to
gel in tissue culture inserts (Falcon) overnight. HaCaT cells (106) were seeded on
top of the gels and cultured submerged overnight to confluency. Confluent
cultures were raised to the air-liquid interface and fed daily from below with
RPMI medium supplemented with 10% fetal bovine serum and antibiotics for 14
days. Rafts were fixed in 4% paraformaldehyde, paraffin embedded, and sec-
tioned.
Soft agar assays. Soft agar plates were prepared by pouring 7 ml of Bacto Agar
medium (1 ml of 23 DMEM-H, 1 ml of fetal bovine serum, 0.1 ml of penicillin-
streptomycin, 6.9 ml of 13 DMEM, 1 ml of 5% Bacto Agar in water), incubated
at 39°C (the agar was preheated to 52°C before addition), into 60-mm-diameter
dishes. The agar was allowed to solidify and overlaid with 2 ml of Bacto Agar
medium containing 4.67 3 104 cells. The cultures were fed weekly with 0.5 ml of
DMEM-H containing antibiotics for 3 weeks. In some experiments, the phos-
phatidylinositol-3-kinase (PI3-kinase) inhibitor LY294002 was added to the agar
medium to a concentration of 10 mM and replenished in DMEM-H upon feed-
ing. All assays were performed in triplicate.
Tumorigenicity studies. Parental HaCaT, vector control, and LMP2A-express-
ing cells were trypsinized, washed extensively with phosphate-buffered saline
solution, and adjusted to a concentration of 5 3 106 cells in a 100-ml total
volume. The cells were subcutaneously injected into 3- to 5-week-old nude mice,
and the appearance of tumors was monitored. Mice were sacrificed when tumor
volumes reached 1 cm3. For proliferation studies, mice were injected intraperi-
toneally with 50 mg of bromodeoxyuridine (BrdU) per kg of body weight three
times at 20-min intervals prior to sacrifice. Tumors were divided and frozen for
preparation of tissue lysates or fixed in 4% paraformaldehyde for histological
analysis. All animals were examined for the presence of metastases.
Preparation of tumor lysates and immunoblots. Frozen tissues were homog-
enized in a Dismembrator (Braun) for 30 s and extracted with NP-40 lysis buffer
(1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-Cl [pH 7.5], 20 mM EDTA, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride). Equal amounts of protein were
separated by sodium dodecyl sulfate–8% polyacrylamide gel electrophoresis and
transferred to Immobilon P membranes (Millipore). Polyclonal anti-HA anti-
body and a monoclonal anti-involucrin antibody were obtained from Santa Cruz
and Sigma, respectively. The anti-active Akt antibody (New England Biolabs)
recognizes phosphorylation of serine 473 and was used at a dilution of 1:1,000.
Detection of total Akt was performed with a polyclonal antibody obtained from
New England Biolabs and used at a dilution of 1:1,000. A monoclonal anti-E-
cadherin antibody was purchased from Upstate Biotechnologies and used at a
dilution of 1:2,500. Wortmannin was added for 30 min at a concentration of 0.1
mM to inhibit PI3-kinase in vitro.
Immunohistochemistry. Immunohistochemical analysis was performed with
the LSAB1 immunohistochemistry kit (DAKO) in accordance with the manu-
facturer’s specifications. For all stains, epitope retrieval by digestion with trypsin
was performed prior to application of the primary antibody. The anti-involucrin
monoclonal antibody was used at a dilution of 1:50. HA stains were performed
with a polyclonal antibody at a 1:40 dilution. BrdU incorporation was detected
with a BrdU staining kit (Oncogene Research Products) used in accordance with
the manufacturer’s instructions.
RESULTS
LMP2A expression in HaCaT cells. The LMP2A cDNA,
tagged with an HA epitope at the C terminus, was subcloned
into the retroviral expression vector pBabe containing the pu-
romycin resistance gene to allow selection of transduced cells.
Infectious replication-deficient recombinant virus was pro-
duced by transient transfection into human 293T cells together
with the gag-pol and env genes (VSV-G). HaCaT cells were
transduced with retrovirus-containing 293T cell culture super-
natant, and infected cells were selected for puromycin resis-
tance. Resistant cells were pooled and assayed for LMP2A
expression by anti-HA Western blotting (see below). Pools
expressing the highest levels of LMP2A were used for future
studies.
Characteristics of LMP2A-expressing HaCaT cells in orga-
notypic raft cultures. The organotypic raft culture system has
been used as an in vitro model for squamous epithelial cell
differentiation (2). Epithelial cells are seeded onto a collagen
gel containing feeder fibroblasts and grown under submerged
conditions. When confluence is reached, the cells are lifted to
the air-liquid interface and fed from below through the colla-
gen-fibroblast layer. Over the course of 14 to 21 days, the
epithelial cells form multiple layers and exhibit characteristics
of differentiated epithelia such as the formation of nonprolif-
erating suprabasal layers, upregulation of proteins of the cor-
nified envelope, and specific distribution of keratins. HaCaT
cells have previously been examined for their behavior in or-
ganotypic culture and exhibit many features of normal strati-
fied epithelium when cultured under these conditions (52).
Raft cultures derived from LMP2A-expressing HaCaT cells
showed a morphology strikingly different from that of vector
control rafts. The LMP2A-expressing rafts were thickened and
the cells were more rounded with large nuclei in comparison to
the flattened appearance of vector control cells (Fig. 1A and
B). Enucleated cells were detectable in the most suprabasal
layers of vector control rafts only. To confirm that the cells re-
tained LMP2A expression under these culture conditions, im-
munohistochemical analysis was performed. While only back-
ground staining was detected with anti-HA antibodies in the
vector control rafts, a discrete membrane-staining pattern, sug-
gestive of LMP2A, was evident in LMP2A-expressing rafts in
all cell layers (Fig. 1C and D). These data indicate that LMP2A
was expressed throughout the time in culture and in the su-
prabasal layers.
To determine if the overall thickening of the LMP2A-ex-
pressing raft cultures reflected an increased rate of prolifera-
tion, vector control and LMP2A-expressing rafts were labeled
with BrdU prior to harvesting and BrdU incorporation was
monitored by immunohistochemistry assay to detect DNA-
synthesizing cells (Fig. 1E and F). Single scattered BrdU-pos-
itive cells were detected in the vector control cultures, whereas
the number of proliferating cells was greatly increased in the
LMP2A-expressing rafts. In addition, the proliferating cells
were not restricted to the basal cell layer, as expected for nor-
mal differentiated epithelia, but were present in all cell layers.
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LMP2A inhibits epithelial cell differentiation. To determine
possible effects of LMP2A expression on epithelial cell differ-
entiation, the expression of markers of differentiation was ex-
amined. Involucrin, a suprabasal precursor protein of the cor-
nified envelope, is expressed in stratified keratinizing epithelia
and is indicative of squamous differentiation (4, 54). Involucrin
expression was detected in the upper two layers of vector
control epithelium but was not observed in the LMP2A-ex-
pressing rafts (Fig. 1G and H). These data, together with the
absence of enucleated cells in the top layers of LMP2A-ex-
FIG. 1. Characterization of HaCaT cell organotypic raft cultures. Hematoxylin-eosin stains of vector control (A) and LMP2A-expressing (B) HaCaT rafts are
shown. LMP2A rafts are thickened with rounded cells containing large nuclei. Cells in vector control rafts are flattened, and enucleated cells are evident in the top layers
of the culture. LMP2A expression was detected in the plasma membrane of cells in all layers of the epithelium using a rabbit HA antiserum and a biotin-streptavidin-
peroxidase detection system (DAKO) (D). Background staining is evident in vector control rafts (C). Cell proliferation was determined by BrdU incorporation and
staining with an anti-BrdU monoclonal antibody. Single BrdU-positive cells were observed in vector control rafts (E), while LMP2A-expressing rafts were highly
proliferative (F). Localization of proliferating cells was not restricted to the basal cell layer. LMP2A blocks cell differentiation. The differentiation marker involucrin
was present in the topmost layers of the epithelium of vector control rafts (G) but was not detected in LMP2A-expressing rafts (H).
VOL. 74, 2000 LMP2A TRANSFORMATION OF EPITHELIAL CELLS 10683
pressing rafts and the presence of proliferating suprabasal
cells, demonstrate that LMP2A expression interferes with the
ability of epithelial cells to differentiate.
LMP2A expression in HaCaT cells confers anchorage inde-
pendence. The ability to grow independently of attachment to
a matrix is a hallmark of malignantly transformed cells. There-
fore, parental, vector control, and LMP2A-expressing HaCaT
cells were tested for the ability to grow in soft agar. LMP2A-
expressing cells rapidly formed numerous colonies after ap-
proximately 1 week in culture, whereas vector control cells and
parental cells did not grow (Fig. 2A and B). Three indepen-
dently established pools of LMP2A-expressing HaCaT cells
infected with separately prepared virus stocks tested positive
for anchorage independence. Parental HaCaT cells and three
independently established pools of vector control cells were
reproducibly unable to grow in soft agar. Representative re-
sults of an experiment conducted in triplicate are presented in
Table 1. The colonies were counted in five random microscopic
fields at low magnification for each cell line.
Tumorigenicity in nude mice. The altered properties of
HaCaT LMP2A cells observed in organotypic culture and the
ability to grow in soft agar suggested that these cells were trans-
formed. To determine whether LMP2A expression confers tu-
morigenicity, parental HaCaT, vector control, and LMP2A-ex-
pressing cells were injected subcutaneously into nude mice.
LMP2A-expressing cells rapidly formed tumors in all of the
animals 1 to 2 weeks postinjection, while vector control and
parental HaCaT cells were significantly less tumorigenic (Ta-
ble 1). One out of three animals injected with parental HaCaT
cells and three out of six animals injected with vector control
cells developed small tumors more than 8 weeks after injec-
tion. The LMP2A-negative tumors grew slowly and remained
small. Hematoxylin-eosin stains of tumor sections revealed ho-
mogeneous cell morphology in the LMP2A-induced tumors
with pale-staining pleomorphic nuclei, prominent nucleoli, and
abundant mitotic figures (Fig. 3B and D). Evidence of squa-
mous differentiation with polarized basal and suprabasal flat-
tened cells was not observed. In contrast, a tumor formed by
parental HaCaT cells was well differentiated with polarized
cells, obvious squamous differentiation, abundant keratin ex-
pression, and well-developed keratin pearls (Fig. 3A and C).
HaCaT vector control cells also formed well-differentiated tu-
mors (data not shown). The overall appearance of the LMP2A
tumors strikingly resembled poorly differentiated or nonkera-
tinizing squamous cell carcinomas similar to NPC. Interest-
ingly, the LMP2A tumors were highly vascularized, containing
abundant blood vessels, in contrast to the parental tumors.
The rapid appearance of LMP2A tumors suggested a highly
proliferative phenotype. Actively proliferating cells were la-
beled by intraperitoneal injection of BrdU into animals prior
to sacrifice and detected by immunohistochemical staining of
tumor sections (Fig. 3E and F). On average, approximately 20
to 30% of the cells in LMP2A tumors and up to 50% of the cell
population in certain areas of the tumors stained positive for
BrdU incorporation while BrdU staining was undetectable in
the HaCaT parental tumor, confirming the differences ob-
served in raft cultures and the difference in growth rate be-
tween LMP2A and control tumors. These data suggest that
LMP2A expression induces tumorigenicity in HaCaT cells. In
agreement with the data obtained with the organotypic raft
cultures, LMP2A-expressing HaCaT cells were impaired in the
ability to differentiate and were highly proliferative in vivo.
LMP2A tumors are metastatic. The rapidity with which
LMP2A tumors appeared soon after injection suggested a very
aggressive malignant phenotype. Therefore, animals with tu-
mors were examined for the presence of metastases. Approx-
imately 55% of the animals had lymph node metastases. Mes-
enteric and subhepatic lymph nodes, but not cervical lymph
nodes, were primarily affected. One animal had a highly vas-
cularized abdominal mass (Table 1). Metastatic tissues were
highly proliferative with a high percentage of cells staining
positive for BrdU incorporation (data not shown). Histological
examination of metastatic tissues revealed complete replace-
ment of lymphoid tissue with epithelial cells (data not shown).
In some animals, the tumors invaded the abdominal cavity
through the adjacent muscle and connective tissues. These
results illustrate the aggressive phenotype of LMP2A-induced
tumors in nude mice, which might provide an excellent in vitro
model system with which to study mechanisms of metastasis.
Molecular analysis of LMP2A tumors. To confirm that
LMP2A expression was retained during growth in vivo, its
FIG. 2. LMP2A-expressing HaCaT cells are anchorage independent. Vector
control or LMP2A-expressing cells (6.7 3 104) were cultured in soft agar for 3
weeks. Vector control cells formed only small clumps of cells (A). Efficient
colony formation was detected only in the HaCaT LMP2A cells (B). Growth in
soft agar is PI3-kinase dependent. Colony formation was inhibited with a signif-
icant decrease in colony size in dishes treated with the PI3-kinase inhibitor
LY294002 at 10 mM (D) but not in dimethyl sulfoxide-treated control dishes (C).
TABLE 1. Summary of soft agar assay results and tumorigenicity dataa





No. of animals with
metastases/total
Organs or area involved
(no. of mice)
Parental HaCaT 0 1/3 .8 0/3 None
HaCaT vector 0 3/6 .8 0/6 None
LMP2A HaCaT 206 18/18 1–2 10/18 Mesenteric and subhepatic LNc (10), abdomen (1)
a Vector control and LMP2A-expressing HaCaT cells were cultured in soft agar for 3 weeks, and colonies were counted in five random microscopic fields at 35
magnification. Tumor formation was assayed after subcutaneous injection of cells into nude mice. Of the animals injected with LMP2A-expressing cells, 55% developed
metastases involving mainly lymphoid tissues. Several animals had multiple-organ involvement.
b Weeks postinjection.
c LN, lymph nodes.
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expression in tumors, HaCaT vector control cells, and Ha-
CaT LMP2A-expressing cells grown in vitro was determined
by immunoblot analysis. The level of LMP2A expression was
strikingly elevated in LMP2A tumors compared to that in cells
grown in tissue culture, suggesting that selection for cells ex-
pressing high levels of LMP2A occurred during tumor forma-
tion (Fig. 4A). The levels of LMP2A in the tumor cells were
also considerably higher than in a single EBV-infected cord
blood cell line (data not shown). However, levels of LMP2A
expression can vary significantly between individual lympho-
blastoid cell lines (41). As expected, LMP2A was absent from
the parental tumor and was expressed at high levels in a met-
astatic mesenteric lymph node but not in an unaffected cervical
lymph node.
Involucrin expression in both the parental HaCaT cells and
the LMP2A tumors was analyzed as a marker of cell differen-
tiation (Fig. 4B). In tissue culture, vector control and LMP2A-
expressing HaCaT cells expressed considerable amounts of
involucrin. In contrast, involucrin levels were greatly decreased
in all of the LMP2A tumors examined while the parental tu-
mor retained a high level of involucrin expression. Involucrin
expression was not detected in the metastatic or unaffected
lymph nodes. These data confirm results obtained in organo-
typic culture, where involucrin expression was also decreased
in LMP2A-expressing cells.
Cadherins are a class of cell surface molecules predomi-
nantly involved in maintaining cell-cell contact through adhe-
rens junctions. There have been numerous reports of altered
FIG. 3. LMP2A expression induces tumorigenicity in nude mice. Hematoxylin-eosin stains of tumor sections of a parental tumor (A and C) and an LMP2A-induced
tumor (B and D) are shown. Parental or LMP2A-expressing HaCaT cells (5 3 106) were injected subcutaneously into nude mice. The parental tumor, which appeared
.8 weeks postinjection, was well differentiated, with a distinction between polarized and squamous cells. Abundant keratin whorls were detected. LMP2A tumors,
which appeared after 1 to 2 weeks, were poorly differentiated. The cells contained large pleomorphic nuclei with distinct nucleoli. Blood vessels were abundant. No
signs of differentiation were detected. (E and F) LMP2A-induced tumors were highly proliferative. Prior to sacrifice, animals were injected three times with BrdU at
50 mg/kg of body weight at 20-min intervals. Proliferating cells in the parental tumor (E) and the LMP2A tumor (F) were detected with an anti-BrdU antibody.
Approximately 20 to 30% of the cells in LMP2A tumors stained positive for BrdU. Magnifications, A, B, E, and F, 320; C and D, 380.
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levels of cadherin expression in human cancers (5, 7). Cad-
herins are required for intercellular contact and the mainte-
nance of epithelial integrity. Loss of cadherin expression is
often correlated with increased invasion and is found predom-
inantly in poorly differentiated tumors, whereas differentiated
carcinomas often retain normal levels of cadherin expression.
Expression of E-cadherin was examined by immunoblot assay
of lysates from vector control and LMP2A-expressing HaCaT
cells, as well as tumor lysates. Interestingly, E-cadherin was
readily detectable only in HaCaT vector control cells and not
in LMP2A-expressing cells grown in vitro or in LMP2A tumors
(Fig. 4C). These results suggest that downregulation of cad-
herin expression is involved in the pronounced metastatic be-
havior of LMP2A tumors.
Cell adhesion signaling and MAPK pathways are not acti-
vated in LMP2A tumors. A previous study indicated that
LMP2A became phosphorylated upon plating onto extracellu-
lar matrix (ECM) proteins (50). Integrin-ECM interactions
lead to activation of the focal adhesion kinase Fak and also to
subsequent activation of the MAPK pathway (28). MAPK is
activated by both integrin and growth factor signaling and is an
important signal transduction pathway involved in cell prolif-
eration and survival (30, 50). Therefore, it was important to
determine if these pathways are affected by LMP2A expres-
sion. Detection of total Fak expression revealed that its levels
are decreased in LMP2A tumors compared to vector control
and LMP2A-expressing cells in culture (Fig. 5, top panel). Fak
becomes phosphorylated on tyrosine when activated, and the
levels of phosphorylated Fak increased upon fibronectin stim-
ulation in both vector control and LMP2A-expressing cells.
However, phosphorylated Fak was not detected in the LMP2A
tumors, suggesting that this pathway was not activated by
LMP2A expression in vivo (Fig. 5, second panel). This was
confirmed by investigation of the phosphorylation status of the
cytoskeletal protein paxillin, a substrate of Fak and Src. Ty-
rosine phosphorylation of paxillin was readily stimulated by
adhesion of tissue culture cells to fibronectin but was not de-
tected in LMP2A tumors (Fig. 5, third panel). In addition,
activation of MAPKs, as illustrated by ERK2, could be stimu-
lated in vitro in both LMP2A-expressing and vector control
cells, while activated ERK1 and ERK2 were not detected in
the LMP2A tumors (Fig. 5, bottom panel). These data indicate
that LMP2A expression does not inhibit integrin-mediated Fak
activation, nor is Fak or MAPK activated as a component of
the transformed, tumorigenic phenotype.
LMP2A activates PI3-kinase–Akt signaling. LMP2A has
been shown to affect the PI3-kinase pathway in B lymphocytes
(35). The regulatory 85-kDa regulatory subunit of PI3-kinase is
constitutively phosphorylated to higher levels in LMP2A-ex-
pressing B cells; however, increased activation of PI3-kinase by
BCR signaling is blocked by LMP2A. Activation of the PI3-
kinase pathway leads to phosphorylation and activation of Akt,
a serine-threonine kinase which is implicated in activation of
NFkB and inhibition of apoptosis (14, 15, 17, 20, 25, 40, 47).
Although the levels of Akt protein were similar in the control
and LMP2A-expressing cell lines, activated Akt was detected
only in LMP2A-expressing cells (Fig. 6A). Similar to the in-
creased levels of LMP2A in the tumors, considerably elevated
levels of activated Akt were detected in the LMP2A tumors,
with no activated Akt in the parental tumor. Wortmannin, a
PI3-kinase inhibitor, completely blocked Akt activation in both
vector control and LMP2A-expressing cells in vitro, confirming
that Akt activation is mediated through PI3-kinase in these
cells. In addition, a second specific inhibitor of PI3-kinase,
LY294002, significantly decreased the overall number and size
of HaCaT LMP2A colonies formed in soft agar (Fig. 2C and
D). These data indicate that LMP2A activation of Akt is me-
diated by PI3-kinase and suggest that the altered growth prop-
erties, manifested by anchorage-independent growth, are de-
pendent on PI3-kinase activation.
Akt activation involves both lipid second messengers and
phosphorylation events. Phosphoinositols created by PI3-ki-
FIG. 4. Immunoblot analysis of tumor lysates. (A) LMP2A expression de-
tected with anti-HA polyclonal serum. Tumors expressed high levels of LMP2A
(LIT1 to 3). LMP2A expression was not detected in a tumor arising form pa-
rental HaCaT cells (PT) or in a normal cervical lymph node (CLN). In contrast,
a metastatic mesenteric lymph node (MLN) expressed high levels of LMP2A. (B)
Involucrin expression detected with a mouse monoclonal antibody. Expression of
involucrin was greatly decreased in LMP2A tumors, whereas fairly high levels
were observed in both LMP2A and vector control cells in tissue culture. (C)
LMP2A-expressing cells and tumors lose expression of E-cadherin. E-cadherin
was detected by immunoblotting.
FIG. 5. LMP2A does not activate cell adhesion signaling or the MAPK
pathway. Levels of focal adhesion kinase, Fak, expression in whole-cell extracts
of the vector control, LMP2A-expressing cells, and tumors (LIT) are shown in
the top panel. Phosphotyrosine (pTyr) immunoprecipitation (IP) from lysates of
suspended (S) or adherent (A) fibronectin-stimulated cells and tumor lysates,
followed by Fak and paxillin blotting, is shown in the second and third panels.
Cell adhesion stimulates Fak and paxillin phosphorylation. Neither Fak nor
paxillin was phosphorylated significantly in LMP2A tumors. MAPK activation
was detected with an antibody recognizing the dually phosphorylated activated
form. Cell adhesion to fibronectin stimulated ERK2, whereas neither ERK1 nor
ERK2 was activated in LMP2A tumors (bottom panel).
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nase bind to the pleckstrin homology domain of Akt, targeting
it to the membrane, where phosphorylation of positive regu-
latory sites at threonine 308 and serine 473 occurs (20). One of
the kinases implicated in positive regulation of Akt is 3-phos-
phoinositide-dependent protein kinase 1, which is activated
through the PI3-kinase pathway (1). 3-Phosphoinositide-de-
pendent protein kinase 1 also activates the ribosomal protein
S6 kinase, a key regulator of the biosynthesis of components of
the protein translation machinery (1, 3, 18). To determine if
activation of PI3-kinase induces the activation of S6 kinase, S6
kinase was identified on immunoblots using antibodies that
recognize the phosphorylated activated form. A low level
of activated S6 kinase was observed in vector control and
LMP2A-expressing HaCaT cells but was not detected in
LMP2A tumors (Fig. 6B). These data indicate that not all
PI3-kinase dependent pathways are activated by LMP2A and
that Akt seems to be selectively targeted.
DISCUSSION
The data presented here reveal that LMP2A is able to in-
duce epithelial cell transformation. LMP2A-expressing HaCaT
cells formed hyperplastic, undifferentiated raft cultures, read-
ily formed colonies in soft agar, and induced the formation
of aggressive, poorly differentiated, and metastatic tumors in
nude mice. Another EBV latent membrane protein, LMP1,
has been shown to induce tumorigenicity and transformation
of primary rodent fibroblasts and to inhibit differentiation of a
squamous carcinoma cell line, SCC12F, in organotypic culture
(16). However, LMP1-expressing HaCaT cells formed well-
differentiated tumors in SCID mice and terminal differentia-
tion in suspension culture was not inhibited by LMP1 (39). In
addition, LMP1 HaCaT cell tumors appeared slowly 6 to 8
weeks postinjection, in contrast to LMP2A-expressing HaCaT
cells, which formed aggressive metastatic neoplasms 1 to 2
weeks after inoculation. The LMP2A tumors were also poorly
differentiated, in contrast to LMP1-induced HaCaT tumors.
The same undifferentiated phenotype observed in organotypic
culture suggests that inhibition of differentiation is an impor-
tant consequence of LMP2A expression in epithelial cells. In-
hibition of differentiation and thickening of the suprabasal
layers by LMP2A have also recently been observed in another
immortalized keratinocyte cell line, FEP 1811, in organotypic
culture (19).
Histologically, the LMP2A tumors were similar to unkera-
tinizing or poorly differentiated NPC tumors. LMP2A tumors
were surprisingly metastatic, with an incidence of approxi-
mately 55%. Metastases were restricted mainly to lymphoid
organs, involving lymph nodes adjacent to the site of inocula-
tion. This is very similar to NPC, where 75 to 80% of patients
initially present with cervical lymph node metastases. It is in-
teresting that signs of invasion into the matrix were not evident
in organotypic culture, suggesting that other factors, such as
paracrine signaling in the animal, might contribute to the de-
velopment of metastases. Furthermore, the noted loss of cad-
herin expression in tumor tissue points to a possible mecha-
nism by which cells lose their adhesion to neighboring cells,
allowing them to break away from the primary tumor and
invade through the ECM, thereby initiating the metastatic
process. It is also interesting that LMP2A-expressing HaCaT
cells expressed considerable amounts of involucrin in tissue
culture and that involucrin levels were greatly decreased dur-
ing tumor formation. In contrast, cadherin expression was lost
in LMP2A-expressing tissue culture cells prior to tumor for-
mation. This loss of cadherin expression may also contribute to
the inhibition of cell differentiation.
The MAPK cascade, one of the major proliferative signal
transduction pathways, was not activated in LMP2A-express-
ing cells or tumors, whereas PI3-kinase-dependent activation
of Akt, a molecule that has been implicated in the inhibition of
apoptosis and in NFkB activation, was observed. Some of the
effects mediated by Akt include phosphorylation of Bad and
phosphorylation of the forkhead transcription factor (FKHR).
Phosphorylated Bad binds to 14-3-3 proteins, which prevents
formation of proapoptotic Bad/Bcl-2 or Bad/BclXL hetero-
dimers (24, 57). The forkhead family of transcription factors
plays a pivotal role in the regulation of cell proliferation and
differentiation. It has been shown that Akt phosphorylates
FKHR1, an event that prevents FKHR1 entry into the nucleus
(6). A potential link between Akt activation and differentiation
has also been implied (48). Ribosomal S6 kinase is important
in the control of the cellular protein translation machinery and
has been linked to the control of cell proliferation (18). Al-
though activation of both Akt and S6 kinase is PI3-kinase
dependent (43), S6 kinase was not activated significantly in
LMP2A-expressing tissue culture cells and its activated form
was not detected in LMP2A tumors. This finding indicates that
PI3-kinase-dependent activation of Akt by LMP2A is uncou-
pled from S6 kinase activation. Elucidation of the mechanism
of this differential regulation will provide important insight
into the control of PI3-kinase signaling and its downstream
effectors. While this work was in progress, LMP2A-mediated
activation of Akt in B cells was also detected (R. Longnecker,
personal communication). As HaCaT is an immortalized cell
line, it is likely that the activation of Akt by LMP2A, in com-
bination with other genetic changes unique to HaCaT cells,
contributes to the aggressive tumorigenic phenotype of these
cells. Continued study of LMP2A-expressing HaCaT cells will
identify the critical events and activated pathways that result in
striking changes in growth properties, tumorigenicity, and me-
tastasis.
We had previously shown that LMP2A interacts with epi-
thelial cell ECM signaling pathways in epithelial cells and that
signaling molecules different from those in B cells functionally
FIG. 6. LMP2A expression activates Akt in a PI3-kinase-dependent fashion.
(A) Immunoblot analysis with an antibody recognizing the activated form, phos-
phorylated on serine 473 (top). Akt activity is higher in LMP2A-expressing tissue
culture cells and LMP2A tumors than in vector control cells. No activated (act.)
Akt is detectable in a parental tumor (PT). PI3-kinase inhibition by wortmannin
treatment for 30 min prior to harvesting of the cells leads to inhibition of Akt
activity. Akt is expressed at similar levels in all of the cells and tissues examined
(bottom). (B) Ribosomal S6 kinase is not activated by LMP2A expression. Tissue
culture cell and LMP2A tumors (LIT) were analyzed by immunoblotting with an
antibody that recognized the phosphorylated activated form of S6 kinase (top).
S6 kinase levels are similar in all of the cells and tissues examined (bottom).
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interact with LMP2A in epithelial cells (51). It is possible
that signaling events elicited by integrin engagement lead to
LMP2A phosphorylation and that LMP2A modulates some
component of integrin signaling. A recent study demonstrated
that PI3-kinase activation by the a6b4 integrin leads to an
invasive phenotype (53), and adhesion of epithelial cells to
their ECM leads to protection from apoptosis through activa-
tion of PI3-kinase–Akt signaling (26). Constitutively active
PI3-kinase has been shown to allow cells to grow anchorage
independently (38). Constitutive activation of this pathway by
LMP2A is likely critical to the anchorage-independent growth
of LMP2A-expressing HaCaT cells. This is supported by the
finding that the PI3-kinase inhibitor LY294002 was able to
potently inhibit colony formation in soft agar.
The data presented here indicate that LMP2A dramatically
affects epithelial cell growth and differentiation and that these
effects are in part mediated through activation of the PI3-
kinase–Akt pathway. LMP2A expression is consistently de-
tected in NPC, and the similarity of the HaCaT LMP2A tu-
mors to NPC suggests that LMP2A also affects epithelial cell
differentiation and growth properties in vivo. It is important to
determine to how LMP2A contributes to the characteristic
properties of NPC and to identify the signaling pathways that
are affected.
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